Fagron has enhanced its EMEA leadership through the acquisitions of Amara in Poland and Magilab in Hungary, contributing to its growth strategy and operational efficiency.

Target Information

Fagron, a global leader in pharmaceutical compounding, has recently acquired the businesses of Amara in Poland and Magilab in Hungary. Amara is a significant player in the Polish compounding sector, boasting over 30 years of operational experience and a portfolio of active registrations vital for conducting business in Poland. This acquisition aims to enhance Fagron's presence and operational leverage in the Polish market.

Meanwhile, Magilab is a renowned brand within Hungary's hospital pharmacy segment, particularly focused on compounding raw materials. This acquisition reinforces Fagron's position in Hungary, a market characterized by high compounding per capita, thus facilitating operational excellence and economies of scale.

Industry Overview

The pharmaceutical industry in Eastern Europe, particularly Poland and Hungary, is experiencing significant growth, driven by increased healthcare expenditures and a rising demand for personalized medicine. I